Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer's disease

FEBS Journal

Volumn 284, Issue 23, 2017, Pages 4083-4095

  Elharram, Ahmed ^a   Czegledy, Nicole M ^a   Golod, Michael ^a   Milne, Ginger L ^b   Pollock, Erik ^c   Bennett, Brian M ^a   Shchepinov, Mikhail S ^d  

^a QUEEN S UNIVERSITY   (Canada)

^b VANDERBILT UNIVERSITY   (United States)

^c Department of Biological Sciences   (United States)

^d Retrotope Inc   (United States)

Author keywords

Alzheimer's disease; cognition; deuterium based therapeutics; lipid peroxidation; polyunsaturated fatty acid

Indexed keywords

DEUTERIUM; ISOPROSTANE DERIVATIVE; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN F2 ALPHA; ALDEHYDE DEHYDROGENASE ISOENZYME 2; ALDH2 PROTEIN, MOUSE; UNSATURATED FATTY ACID;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPUS; LIGHT-DARK TEST; LIPID PEROXIDATION; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SPATIAL MEMORY; WORKING MEMORY; ANIMAL; CHEMISTRY; COGNITION; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; HYDROGENATION; KNOCKOUT MOUSE; MEMORY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALDEHYDE DEHYDROGENASE, MITOCHONDRIAL; ALZHEIMER DISEASE; ANIMALS; COGNITION; DEUTERIUM; DISEASE MODELS, ANIMAL; F2-ISOPROSTANES; FATTY ACIDS, UNSATURATED; HIPPOCAMPUS; HUMANS; HYDROGENATION; LIPID PEROXIDATION; MEMORY; MICE, KNOCKOUT;

EID: 85037067562     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.14291     Document Type: Article

References (72)

1. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97, 1634–1658.
2. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759–767.
3. Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23, 134–147.
4. Butterfield DA (1997) β-Amyloid-associated free radical oxidative stress and neurotoxicity : implications for Alzheimer's disease. Chem Res Toxicol 10, 495–506.
5. Praticò D (2008) Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci 29, 609–615.
6. Di Domenico F, Tramutola A & Butterfield DA (2016) Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders. Free Radic Biol Med 111, 253–261.
7. Uchida K (2003) 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 42, 318–343.
8. Esterbauer H, Schaur RJ & Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11, 81–128.
9. Kawai Y, Takeda S & Terao J (2007) Lipidomic analysis for lipid peroxidation-derived aldehydes using gas chromatography-mass spectrometry. Chem Res Toxicol 20, 99–107.
10. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG et al. (2012) Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69, 836–841.
11. Vellas B, Coley N, Ousset P-J, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P et al. (2012) Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 11, 851–859.
12. Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, Yee M, Crowley J & Schmitt FA (2017) Association of antioxidant supplement use and dementia in the prevention of Alzheimer's disease by vitamin E and selenium trial (PREADViSE). JAMA Neurol 74, 567–573.
13. Halliwell B & Gutteridge JMC (2007) Free Radicals in Biology and Medicine, 4th edn. Oxford University Press, Oxford.
14. Hill S, Hirano K, Shmanai VV, Marbois BN, Vidovic D, Bekish AV, Kay B, Tse V, Fine J, Clarke CF et al. (2011) Isotope-reinforced polyunsaturated fatty acids protect yeast cells from oxidative stress. Free Radic Biol Med 50, 130–138.
15. Shchepinov MS (2007) Reactive oxygen species, isotope effect, essential nutrients, and enhanced longevity. Rejuvenation Res 10, 47–59.
16. Hill S, Lamberson CR, Xu L, To R, Tsui HS, Shmanai VV, Bekish AV, Awad AM, Marbois BN, Cantor CR et al. (2012) Small amounts of isotope-reinforced polyunsaturated fatty acids suppress lipid autoxidation. Free Radic Biol Med 53, 893–906.
17. Andreyev AY, Tsui HS, Milne GL, Shmanai VV, Bekish AV, Fomich MA, Pham MN, Nong Y, Murphy AN, Clarke CF et al. (2015) Isotope-reinforced polyunsaturated fatty acids protect mitochondria from oxidative stress. Free Radic Biol Med 82, 63–72.
18. Westheimer FH (1961) The magnitude of the primary kinetic isotope effect for compounds of hydrogen and deuterium. Chem Rev 61, 265–273.
19. Shchepinov MS, Chou VP, Pollock E, Langston JW, Cantor CR, Molinari RJ & Manning-Boğ AB (2011) Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease. Toxicol Lett 207, 97–103.
20. Berbée JFP, Mol IM, Milne GL, Pollock E, Hoeke G, Lütjohann D, Monaco C, Rensen PCN, van der Ploeg LHT & Shchepinov MS (2017) Deuterium-reinforced polyunsaturated fatty acids protect against atherosclerosis by lowering lipid peroxidation and hypercholesterolemia. Atherosclerosis 264, 100–107.
21. −/− mice as an age-related model of cognitive impairment and Alzheimer's Disease. Mol Brain 8, 27.
22. Picklo MJ, Olson SJ, Markesbery WR & Montine TJ (2001) Expression and activities of aldo-keto oxidoreductases in Alzheimer disease. J Neuropath Exp Neurol 60, 686–695.
23. Yoval-Sánchez B & Rodríguez-Zavala JS (2012) Differences in susceptibility to inactivation of human aldehyde dehydrogenases by lipid peroxidation byproducts. Chem Res Toxicol 25, 722–729.
24. Lovell MA, Ehmann WD, Mattson MP & Markesbery WR (1997) Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18, 457–461.
25. Markesbery WR & Lovell MA (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimerʼs disease. Neurobiol Aging 19, 33–36.
26. McGrath LT, McGleenon BM, Brennan S, McColl D, McIlroy S & Passmore AP (2001) Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. Q J Med 94, 485–490.
27. Reed TT, Pierce WM, Markesbery WR & Butterfield DA (2009) Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res 1274, 66–76.
28. Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR & Butterfield DA (2008) Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimerʼs disease. Neurobiol Dis 30, 107–120.
29. Perluigi M, Sultana R, Cenini G, Domenico FD, Memo M, Pierce WM, Coccia R & Butterfield DA (2009) Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl 3, 682–693.
30. Czegledy NM & Bennett BM (2017) Anxiety- and Depression-like Behaviours in a Mouse Model of Oxidative Stress-induced Cognitive Impairment. Canadian Association for Neuroscience, Montreal, QC.
31. Shchepinov MS, Roginsky VA, Brenna JT, Molinari RJ, To R, Tsui H, Clarke CF & Manning-Bog AB (2014) Deuterium protection of polyunsaturated fatty acids against lipid peroxidation: a novel approach to mitigating mitochondrial neurological diseases. In Omega 3 Fatty Acids in Brain and Neurological Health (Watson RS & De Meester F, eds), pp. 373–383. Elsevier Academic Press, Amsterdam.
32. Lamberson CR, Xu L, Muchalski H, Montenegro-Burke JR, Shmanai VV, Bekish AV, McLean JA, Clarke CF, Shchepinov MS & Porter NA (2014) Unusual kinetic isotope effects of deuterium reinforced polyunsaturated fatty acids in tocopherol-mediated free radical chain oxidations. J Am Chem Soc 136, 838–841.
33. Cotticelli MG, Crabbe AM, Wilson RB & Shchepinov MS (2013) Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids. Redox Biol 1, 398–404.
34. Milne GL, Dai Q & Roberts LJ (2015) The isoprostanes—25 years later. Biochim Biophys Acta 1851, 433–445.
35. Markesbery WR, Kryscio RJ, Lovell MA & Morrow JD (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 58, 730–735.
36. Sultana R, Perluigi M & Butterfield DA (2013) Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer Disease brain. Free Radic Biol Med 62, 157–169.
37. Bradley MA, Xiong-Fister S, Markesbery WR & Lovell MA (2012) Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiol Aging 33, 1034–1044.
38. Long EK & Picklo MJ Sr (2014) Trans-4-hydroxy-2-hexenal, a product of n-3 fatty acid peroxidation: make some room HNE. Free Radic Biol Med 49, 1–8.
39. Long EK, Murphy TC, Leiphon LJ, Watt J, Morrow JD, Milne GL, Howard JR & Picklo MJ Sr (2008) Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation. J Neurochem 105, 714–724.
40. Pawlosky RJ, Bacher J & Salem N Jr (2001) Ethanol consumption alters electroretinograms and depletes neural tissues of docosahexaenoic acid in rhesus monkeys: nutritional consequences of a low n-3 fatty acid diet. Alcohol Clin Exp Res 25, 1758–1765.
41. Lim SY, Doherty JD & Salem N Jr (2005) Lead exposure and (n-3) fatty acid deficiency during rat neonatal development alter liver, plasma, and brain polyunsaturated fatty acid composition. J Nutr 135, 1027–1033.
42. Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, Szeto HH, Park B & Reddy PH (2010) Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 20 (Suppl 2), S609–S631.
43. Feng Y & Wang X (2012) Antioxidant therapies for Alzheimer's disease. Oxid Med Cell Longev 2012, 472932.
44. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336, 1216–1222. Editorial commentary (1997) N Engl J Med 336, 1245–1247.
45. Bowry VW, Ingold KU & Stocker R (1992) Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J 288, 341–344.
46. Ohsawa I, Nishimaki K, Yasuda C, Kamino K & Ohta S (2003) Deficiency in a mitochondrial aldehyde dehydrogenase increases vulnerability to oxidative stress in PC12 cells. J Neurochem 84, 1110–1117.
47. Garaycoechea JI, Crossan GP, Langevin F, Daly M, Arends MJ & Patel KJ (2012) Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 489, 571–575.
48. Duan Y, Gao Y, Zhang J, Chen Y, Jiang Y, Ji J, Zhang J, Chen X, Yang Q, Su L et al. (2016) Mitochondrial aldehyde dehydrogenase 2 protects gastric mucosa cells against DNA damage caused by oxidative stress. Free Radic Biol Med 93, 165–176.
49. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD & Mochly-Rosen D (2008) Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 321, 1493–1495.
50. Guo JM, Liu AJ, Zang P, Dong WZ, Ying L, Wang W, Xu P, Song XR, Cai J, Zhang SQ et al. (2013) ALDH2 protects against stroke by clearing 4-HNE. Cell Res 23, 915–930.
51. Fu SH, Zhang HF, Yang ZB, Li TB, Liu B, Lou Z, Ma QL, Luo XJ & Peng J (2014) Alda-1 reduces cerebral ischemia/reperfusion injury in rat through clearance of reactive aldehydes. Naunyn Schmiedebergs Arch Pharmacol 387, 87–94.
52. Ding J, Zhang Q, Luo Q, Ying Y, Liu Y, Li Y, Wei W, Yan F & Zhang H (2016) Alda-1 attenuates lung ischemia-reperfusion injury by reducing 4-hy- droxy-2-nonenal in alveolar epithelial cells. Crit Care Med 44, e544–e552.
53. Michel TM, Gsell W, Käsbauer L, Tatschner T, Sheldrick AJ, Neuner I, Schneider F, Grünblatt E & Riederer P (2010) Increased activity of mitochondrial aldehyde dehydrogenase (ALDH) in the putamen of individuals with Alzheimer's disease: a human postmortem study. J Alzheimers Dis 19, 1295–1301.
54. Michel TM, Käsbauer L, Gsell W, Jecel J, Sheldrick AJ, Cortese M, Nickl-Jockschat T, Grünblatt E & Riederer P (2014) Aldehyde dehydrogenase 2 in sporadic Parkinson's disease. Parkinsonism Relat Disord 20 (Suppl 1), S68–S72.
55. Kamino K, Nagasaka K, Imagawa M, Yamamoto H, Yoneda H, Ueki A, Kitamura S, Namekata K, Miki T & Ohta S (2000) Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. Biochem Biophysical Res Commun 273, 192–196.
56. Wang B, Wang J, Zhou S, Tan S, He X, Yang Z, Xie Y-C, Li S, Zheng C & Ma X (2008) The association of mitochondrial aldehyde dehydrogenase gene (ALDH2) polymorphism with susceptibility to late-onset Alzheimer's disease in Chinese. J Neurol Sci 268, 172–175.
57. Seitz HK & Meier P (2007) The role of acetaldehyde in upper digestive tract cancer in alcoholics. Transl Res 149, 293–297.
58. Zheng F, Yan H, Liu B, Yue W, Fan L, Liao J, Cui Y, Lu T, Jiang T & Zhang D (2017) ALDH2 Glu504Lys confers susceptibility to schizophrenia and impacts hippocampal-prefrontal functional connectivity. Cereb Cortex 27, 2034–2040.
59. Liu J, Sui S, Xu l, Lin K, Zong J, Yang Y & Wang H (2016) Association of ADH2 and ALDH2 genetic polymorphisms with susceptibility to Parkinson's disease in a Chinese population. Int J Clin Exp Pathol 9, 9436–9442.
60. Zhao CC, Cai HB, Wang H & Pan SY (2016) Role of ADH2 and ALDH2 gene polymorphisms in the development of Parkinson's disease in a Chinese population. Genet Mol Res 15, 1–8.
61. Zhang X, Ye YL, Wang YN, Liu FF, Liu XX, Hu BL, Zou M & Zhu JH (2015) Aldehyde dehydrogenase 2 genetic variations may increase susceptibility to Parkinson's disease in Han Chinese population. Neurobiol Aging 36, 2660.e9–e13.
62. Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, Mash DC, Kopin IJ & Sharabi Y (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem 126, 591–603.
63. Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS & Strong R (2012) Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PLoS One 7, e31522.
64. Luo J, Lee SH, VandeVrede L, Qin Z, Ben Aissa M, Larson J, Teich AF, Arancio O, D'Souza Y, Elharram A et al. (2016) A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease. Mol Neurodegener 11, 35.
65. Berkowitz BA, Lenning J, Khetarpal N, Tran C, Wu JW, Berri AM, Dernay K, Haacke EM, Shafie-Khorassani F, Podolsky RH et al. (2017) In vivo imaging of prodromal hippocampus CA1 subfield oxidative stress in models of Alzheimer's Disease and Angelman Syndrome. FASEB J 31, 4179–4186.
66. Isse T, Oyama T, Kitagawa K, Matsuno K, Matsumoto A, Yoshida A, Nakayama K, Nakayama K & Kawamoto T (2002) Diminished alcohol preference in transgenic mice lacking aldehyde dehydrogenase activity. Pharmacogenetics 12, 621–626.
67. Milne GL, Sanchez SC, Musiek ES & Morrow JD (2007) Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc 2, 221–226.
68. Milne GL, Gao B, Terry ES, Zackert WE & Sanchez SC (2013) Measurement of F2-isoprostanes and isofurans using gas chromatography-mass spectrometry. Free Radic Biol Med 59, 36–44.
69. Menon R, Fortunato SJ, Milne GL, Brou L, Carnevale C, Sanchez SC, Hubbard L, Lappas M, Drobek CO & Taylor RN (2011) Amniotic fluid eicosanoids in preterm and term births: effects of risk factors for spontaneous preterm labor. Obstet Gynecol 118, 121–134.
70. Delpolyi AR, Fang S, Palop JJ, Yu G, Wang X & Mucke L (2006) Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging 29, 253–266.
71. Gould TD, Dai DT & Kovacsics CE (2009) The open field test. Mood and anxiety related phenotypes in mice. Neuromethods 42, 1–20.
72. Bourin M & Hascoet M (2003) The mouse light/dark box test. Eur J Pharmacol 463, 55–65.